These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3191937)

  • 1. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
    N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
    J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE; Cowan DH; Hasselback R
    Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
    Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
    Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
    Björkholm M
    Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose intensity analysis of melphalan and prednisone in multiple myeloma.
    Palmer M; Belch A; Hanson J; Brox L
    J Natl Cancer Inst; 1988 May; 80(6):414-8. PubMed ID: 3367382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
    N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.